Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3647-3652

  Darby, Eric ^a   An, Shaojian ^a   Ng, Chunyung ^a   Hsieh, Tze Chen ^a   Mallouh, Camille ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Estramustine; p53; Prostate carcinoma; Taxol; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRAMUSTINE; PACLITAXEL; VINBLASTINE;

ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL GROWTH; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MICROTUBULE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; ESTRAMUSTINE; HUMANS; MALE; NEOPLASM PROTEINS; PACLITAXEL; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE;

EID: 0030499839     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Boring, CC, Squires, TS and Tong T: Cancer statistics. CA Cancer J Clin 43: 7-26, 1993.
2. Pienta KJ and Coffey DS: Cell motility as a chemotherapeutic target. Cancer Survival 11: 255-265, 1991.
3. Perry CM and McTavish D: Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs aging 7: 49-74, 1995.
4. Rowinsky EK and Donehower RC: Paclitaxel (Taxol). N Engl J Med 332: 1004-1014, 1995.
5. Pienta KJ, Replogle J and Leihs JF: Inhibition of prostate cancer growth by vinblastine and tamoxifen. The Prostate 26: 270-274, 1995.
6. Stearns MB, Wang M, Tew K and Bindes LI: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biology 107: 2647-2656, 1988.
7. Wani MC, Taylor HL, Wall ME, Cogzon P and McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971.
8. Speicher LA, Barone L and Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostate carcinoma cell lines. Cane Res 52: 4433-4440, 1992.
9. Pienta KJ, Replogle J and Leihs JF: Inhibition of prostate cancer growth by vinblastine and tamoxifen. The Prostate 26: 270-274, 1995.
10. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
11. Furihata M, Sonobe H and Ohtsuki Y: The aberrant p53 protein (Review). Int J Oncol 6: 1209-1226, 1995.
12. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T and Lane DP: p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 338: 513-514, 1991.
13. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI and Issacs WB: Allelic loss of chromosome 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87: 8751-8755, 1990.
14. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274-281, 1978.
15. Kaighn ME, Warayan SK, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-20, 1979.
16. Muraki J, Addonizio JC, Choudhury MS, Fischer J, Eshghi M, Davidian MM, Shapiro LR, Wilmot PL, Nagamatsu GR and Chiao JW: Establishment of new human prostate cancer cell line (JCA-1). Urology 36: 79-84, 1990.
17. Chang CC and Wu JM: Modulation of antiviral activity of interferon and 2′,5′oligoadenylate synthetase gene expression by mild hyperthermia (39.5°C) in cultured human cells. J Biol Chem 4605-4612, 1991.
18. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW and Neal DE: p53 expression and clinical outcome in prostate cancer. Br J Urol 72: 778-781, 1993.
19. Seidman AD, Scher HI, Petrylak DD, Dershaw D and Curley T: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147: 931-934, 1992.